Showing posts with label Parabolic Drugs. Show all posts
Showing posts with label Parabolic Drugs. Show all posts
25 February 2013
24 February 2013
07 April 2011
Vineet Gupta, Executive Director, Parabolic Drugs :: IIFL
Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Vineet Gupta, Executive Director, Parabolic Drugs Ltd.
Parabolic Drugs Ltd., incorporated in 1996, is promoted by
professionally qualified first generation entrepreneurs. It is engaged in
manufacturing, including contract manufacturing, of APIs and API intermediates for domestic and
international markets, including regulated markets. It manufactures Semi Synthetic Penicillin (SSP)
and Cephalosporin range of antibiotics, whereby the product portfolio comprises 44 APIs and 7 API
intermediates. The Company has two manufacturing facilities located at Derabassi, Punjab and
Panchkula, Haryana. It also has a custom synthesis and R&D centre at Barwala, Haryana which started
operations in January 2010.
Mr. Vineet Gupta, Executive Director, Parabolic Drugs Ltd. and one of our
Promoters. He is an IIT graduate in Mechanical engineering who is principally
leading the Educational Business of Parabolic Group under the brand Jamboree
Education. At Parabolic Drugs, he is the tactician for the global growth and
marketing network. He is also maintaining relations with the investors of the
company. Besides this, he is a member on the board of the AIESEC Alumni
Association.
Speaking exclusively to Hemant P. Maradia of IIFL, Mr. Gupta says, “We see
the full effect from the ongoing capacity expansion coming forth in the next financial year.”
Do you see the current momentum continuing?
Yes, we do. We have gone in for significant capacity addition in Cephalosporin Oral range of drugs. We
have augmented Cephalosporin Oral capacity by almost 40%. Full scale commercial production has
already started.
We intend to capture some of the topline from the current expansion in the current quarter itself. We
see the full effect from the ongoing capacity expansion coming forth in the next financial year.
There are other expansions coming up as well, and the same will commence in April and June this
year. One is the expansion that we are doing in the Non-Beta Lactam space. That should come up by
April.
We also have the Cephalosporin Sterile facility coming up by June.
All these expansions should eventually add capacity to the tune of Rs. 12bn. How much of that we are
able to capture in the next fiscal year is difficult to tell now; because it takes time for the plant to start
producing at full capacity.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Vineet Gupta, Executive Director, Parabolic Drugs Ltd.
Parabolic Drugs Ltd., incorporated in 1996, is promoted by
professionally qualified first generation entrepreneurs. It is engaged in
manufacturing, including contract manufacturing, of APIs and API intermediates for domestic and
international markets, including regulated markets. It manufactures Semi Synthetic Penicillin (SSP)
and Cephalosporin range of antibiotics, whereby the product portfolio comprises 44 APIs and 7 API
intermediates. The Company has two manufacturing facilities located at Derabassi, Punjab and
Panchkula, Haryana. It also has a custom synthesis and R&D centre at Barwala, Haryana which started
operations in January 2010.
Mr. Vineet Gupta, Executive Director, Parabolic Drugs Ltd. and one of our
Promoters. He is an IIT graduate in Mechanical engineering who is principally
leading the Educational Business of Parabolic Group under the brand Jamboree
Education. At Parabolic Drugs, he is the tactician for the global growth and
marketing network. He is also maintaining relations with the investors of the
company. Besides this, he is a member on the board of the AIESEC Alumni
Association.
Speaking exclusively to Hemant P. Maradia of IIFL, Mr. Gupta says, “We see
the full effect from the ongoing capacity expansion coming forth in the next financial year.”
Do you see the current momentum continuing?
Yes, we do. We have gone in for significant capacity addition in Cephalosporin Oral range of drugs. We
have augmented Cephalosporin Oral capacity by almost 40%. Full scale commercial production has
already started.
We intend to capture some of the topline from the current expansion in the current quarter itself. We
see the full effect from the ongoing capacity expansion coming forth in the next financial year.
There are other expansions coming up as well, and the same will commence in April and June this
year. One is the expansion that we are doing in the Non-Beta Lactam space. That should come up by
April.
We also have the Cephalosporin Sterile facility coming up by June.
All these expansions should eventually add capacity to the tune of Rs. 12bn. How much of that we are
able to capture in the next fiscal year is difficult to tell now; because it takes time for the plant to start
producing at full capacity.
Subscribe to:
Posts (Atom)